1. Home
  2. MEGI vs ACHV Comparison

MEGI vs ACHV Comparison

Compare MEGI & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MainStay CBRE Global Infrastructure Megatrends Term Fund

MEGI

MainStay CBRE Global Infrastructure Megatrends Term Fund

HOLD

Current Price

$14.18

Market Cap

788.0M

Sector

Finance

ML Signal

HOLD

Logo Achieve Life Sciences Inc.

ACHV

Achieve Life Sciences Inc.

HOLD

Current Price

$6.55

Market Cap

726.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MEGI
ACHV
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
788.0M
726.5M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
MEGI
ACHV
Price
$14.18
$6.55
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
★ $14.15
AVG Volume (30 Days)
165.3K
★ 1.3M
Earning Date
01-01-0001
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.25
$2.62
52 Week High
$15.89
$8.64

Technical Indicators

Market Signals
Indicator
MEGI
ACHV
Relative Strength Index (RSI) 56.34 37.54
Support Level $13.25 $6.22
Resistance Level $15.45 $6.64
Average True Range (ATR) 0.22 0.35
MACD 0.09 -0.05
Stochastic Oscillator 80.20 25.40

Price Performance

Historical Comparison
MEGI
ACHV

About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund

NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

Share on Social Networks: